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Abstract
Background: Several aspects concerning the relationship between the metabolic syndrome and incident
diabetes are incompletely understood including the magnitude of the risk estimate, potential gender
differences in the associations between the metabolic syndrome and incident diabetes, the associations
between the components of the metabolic syndrome and incident diabetes, and whether the metabolic
syndrome provides additional prediction beyond its components. To shed light on these issues, we
examined the prospective association between the metabolic syndrome defined by the National
Cholesterol Education Program (NCEP) and International Diabetes Federation (IDF) and diabetes.
Methods: We used data for 2796 men and women aged 35–65 years from the European Prospective
Investigation into Cancer and Nutrition-Potsdam Study followed for an average of 6.9 years. This analysis
employed a case-cohort design that included 697 participants who developed diabetes and 2099
participants who did not. Incident diabetes was identified on the basis of self-reports and verified by
contacting the patient's attending physician.
Results: The adjusted hazard ratio for the NCEP definition was 4.62 (95% confidence interval [CI]: 3.90–
5.48) and that for the IDF definition was 4.59 (95% CI: 3.84–5.50). The adjusted hazard ratios for the NCEP
but not IDF definition were higher for women than men. When participants who had no cardiometabolic
abnormalities were used as the reference group for the NCEP definition, the adjusted hazard ratio for
having 3 or more abnormalities increased to 22.50 (95% CI: 11.21–45.19). Of the five components,
abdominal obesity and hyperglycemia were most strongly associated with incident diabetes.
Conclusion:  In this study population, both definitions of the metabolic syndrome provided similar
estimates of relative risk for incident diabetes. The increase in risk for participants with the metabolic
syndrome according to the NCEP definition was very large when contrasted with the risk among those
who had no cardiometabolic abnormalities.
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Introduction
The concept of the metabolic syndrome can be traced back
to as early as 1923 when an association between hyperten-
sion, uric acid, and hyperglycemia was reported [1]. Since
major organizations started formulating definitions for
this syndrome in 1998, it has been the object of intense
research. Although it has been shown to be a significant
predictor of diabetes, cardiovascular disease, and all-cause
mortality [2], controversy about its importance as a risk
factor remains [3].
The most recent definition of the metabolic syndrome was
developed by the International Diabetes Federation (IDF)
in 2005 [4]. This definition places a major emphasis on
central obesity. Since that time, several reports have exam-
ined the associations between the metabolic syndrome as
defined by the IDF and incident diabetes and compared
these risk estimates to those calculated using other defini-
tions [5-13]. However, several issues remain unresolved
including the presence of potential gender differences in
the risk for incident diabetes associated with the meta-
bolic syndrome and whether the metabolic syndrome
offers additional prediction beyond its components. To
examine these issues and to compare the ability of the
metabolic syndrome to predict the risk of developing dia-
betes using two definitions, namely those of the National
Cholesterol Education Program (NCEP) and IDF, we used
data from a large prospective German study.
Methods
Study population
The European Prospective Investigation into Cancer and
Nutrition (EPIC) Potsdam study is part of the multi-centre
prospective cohort study EPIC [14,15]. In Potsdam, Ger-
many, 27,548 subjects, 16,644 women mainly aged 35–
65 years and 10,904 men mainly aged 40–65 years, from
the general population were recruited between 1994 and
1998 [16]. The baseline examination included anthropo-
metric measurements, a personal interview including
questions on prevalent diseases, and a questionnaire on
socio-demographic and lifestyle characteristics. Follow-up
questionnaires to identify incident cases of diabetes mel-
litus have been administered every 2 to 3 years. Response
rates for each of the three waves of follow-up were about
95%. We also considered questionnaires that were part of
the ongoing fourth wave of follow-up round and were
sent out until January 31st 2005. By August 31st 2005,
90% of them were returned. Consent was obtained from
all participants of the study, and approval was given by
the Ethical Committee of the State of Brandenburg, Ger-
many. The conduct of the study was performed in accord-
ance with principles of the Declaration of Helsinki.
Ascertainment of incident type 2 diabetes
Potentially incident cases of diabetes were those with self-
reports of a diabetes diagnosis, diabetes-relevant medica-
tion, or dietary treatment due to diabetes. All potentially
incident cases were verified by questionnaires mailed to
the diagnosing physician asking about the date and type
of diagnosis, diagnostic tests, and treatment of diabetes.
Only cases with a physician diagnosis of type 2 diabetes
(International Classification of Diseases, 10th Revision:
E11) and a diagnosis date after the baseline examination
were considered as confirmed incident cases of type 2 dia-
betes and were used in the analysis.
Ascertainment of prevalent type 2 diabetes
Self-reported diabetes mellitus at baseline was evaluated
by a study physician using information on self-reported
medical diagnoses, medication records and dieting behav-
ior. Uncertainties regarding a proper diagnosis were clari-
fied with the participant or treating physician. We also
used plasma concentrations of glucose to define prevalent
diabetes. Because many participants did not provide fast-
ing blood samples, we defined diabetes as a fasting
plasma glucose ≥ 126 mg/dl or a nonfasting plasma glu-
cose of ≥ 200 mg/dl.
Case-cohort construction
The case-cohort consisted of a random sample of partici-
pants from the full cohort and all participants from the
full cohort who developed incident diabetes. Thus, a ran-
dom sample of 2,500 participants (subcohort) was drawn
from the participants of the full cohort who had blood
samples available (26,444 of 27,548). After excluding par-
ticipants with prevalent diabetes and missing information
for study covariates, the subcohort included 2,165 partic-
ipants. Of the 801 participants from the full cohort with
blood samples who developed incident diabetes, 697
remained for analyses after the exclusion criteria were
applied. Because the subcohort is representative of the full
cohort at baseline in case-cohort studies, the random sam-
ple of the full cohort included 66 of the 697 subjects who
developed incident type 2 diabetes during follow-up.
Metabolic syndrome
According to the IDF definition, someone has the meta-
bolic syndrome if he or she has central adiposity plus ≥ 2
of the following four factors [4]:
1. raised concentration of triglycerides: ≥ 150 mg/dl (1.7
mmol/L) or specific treatment for this lipid abnormality;
2. reduced concentration of high-density lipoprotein cho-
lesterol: < 40 mg/dl (1.03 mmol/L) in males and < 50 mg/
dl (1.29 mmol/L) in females or specific treatment for this
lipid abnormality;Cardiovascular Diabetology 2008, 7:35 http://www.cardiab.com/content/7/1/35
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3. raised blood pressure: systolic blood pressure ≥ 130
mmHg or diastolic blood pressure ≥ 85 mmHg or treat-
ment of previously diagnosed hypertension;
4. raised fasting plasma glucose ≥ 100 mg/dl (5.6 mmol/
l) or previously diagnosed type 2 diabetes.
For this study of German participants, we used a waist cir-
cumference threshold of ≥ 94 cm for men and ≥ 80 cm for
women.
Using the 2004 National Heart, Lung, and Blood Insti-
tute/American Heart Association revision of the original
NCEP criteria, participants who had three or more of the
following criteria were defined as having the metabolic
syndrome [17,18]: 1. abdominal obesity (waist circumfer-
ence >102 cm in men and >88 cm in women); 2. concen-
tration of triglycerides ≥ 150 mg/dl (1.7 mmol/l); 3.
concentration of high-density lipoprotein cholesterol <40
mg/dl (1.03 mmol/l) in men and <50 mg/dl (1.29 mmol/
l) in women; 4. a systolic blood pressure > = 130 mmHg
or a diastolic blood pressure ≥ 85 mmHg); and 5. fasting
glucose ≥ 100 mg/dl (5.6 mmol/l). The participants who
currently reported using antihypertensive were counted as
having high blood pressure.
Anthropometric measurement procedures followed
standard protocols under strict quality control [19,20].
Three measurements of systolic blood pressure and
diastolic blood pressure from participants in the sitting
position were recorded. The average of the last two read-
ings was used. Concentrations of triglycerides, high-den-
sity lipoprotein cholesterol, and glucose were measured
using the ADVIA 1650 chemistry system (Siemens Medi-
cal Solutions, Erlangen, Germany).
Covariates
We included the following covariates from the baseline
data collection: age, sex, educational attainment, occupa-
tional activity, physical activity level, alcohol consump-
tion, and concentrations of total cholesterol and C-
reactive protein. Information on educational attainment,
smoking, occupational activity, and physical activity were
assessed with a self-administered questionnaire and a per-
sonal interview. For physical activity, we considered par-
ticipation in sports and bicycling, both calculated as the
average time spent per week during the 12 months before
baseline recruitment. Alcohol use was assessed as part of
the food frequency questionnaire. Concentrations of total
cholesterol and C-reactive protein, and glucose were
measured using the ADVIA 1650 chemistry system (Sie-
mens Medical Solutions, Erlangen, Germany).
Statistical analyses
The agreement in the classification of the metabolic syn-
drome using the two definitions was done with the kappa
statistic. Differences in baseline characteristics by incident
diabetes status were tested with Kruskal-Wallis tests for
continuous variables and with Fisher's exact tests or chi-
square tests for categorical variables. Cox proportional
hazards analysis, using Prentice's pseudo-likelihood
approach in the computations [21], was used to estimate
hazard ratios and 95% confidence intervals. Age was used
as the primary time dependent variable in all models,
with entry time defined as the subject's age at recruitment
and exit time as the date of diagnosis of diabetes, death,
or return of the last follow-up questionnaire. Analyses
were adjusted for baseline information including sex, edu-
cational attainment (in or no training, vocational train-
ing, technical school, technical college or university
degree), smoking (never, past, current <20 cigarettes/d,
current  ≥ 20 cigarettes/d), occupational activity (light,
moderate, heavy), physical activity (continuous as h/
week), alcohol intake (<0.1 g/d, 0.1–5.0 g/d, 5.1–10.0 g/
d, 10.1–20.0 g/d, 20.1–40.0 g/d, >40.0 g/d), and concen-
trations of total cholesterol (continuous) and C-reactive
protein (continuous). All analyses were performed with
SAS release 9.1 (SAS Institute, Cary, NC).
Results
Our final sample included 1186 men (397 events) and
1610 women (300 events). The mean and median follow-
up times were 6.9 and 6.5 years, respectively. The preva-
lence of the metabolic syndrome according to the NCEP
definition in the subcohort was 22.5% among all partici-
pants, 29.1% in men, and 18.5% in women. The preva-
lence of the metabolic syndrome according to the IDF
definition in the subcohort was 28.3% among all partici-
pants, 33.2% in men, and 25.2% in women. The percent
agreement between the two definitions was 87.4% (kappa
= 0.67, 95% confidence interval [CI]: 0.63, 0.70) for all
participants, 83% (kappa = 0.60, 95% CI: 0.54, 0.66) in
men, and 90.2% (kappa = 0.72, 95% CI: 0.67, 0.76) in
women.
At baseline, participants of the subcohort who developed
diabetes were significantly more likely to be older, to have
a larger waist circumference, higher systolic blood pres-
sure, higher concentrations of total cholesterol, triglycer-
ides, glucose, and C-reactive protein, and lower
concentrations of high-density lipoprotein cholesterol
than participants who did not develop diabetes (Table 1).
Furthermore, participants who developed diabetes were
far more likely to have had the metabolic syndrome at
baseline than those who did not develop diabetes. Levels
of physical activity, the percentage of participants who
had never smoked, and the percentage of participants whoCardiovascular Diabetology 2008, 7:35 http://www.cardiab.com/content/7/1/35
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consumed ≥ 40 grams of alcohol per day were not signifi-
cantly different between the two groups.
Both definitions were significant predictors of incident
diabetes (Table 2). The adjusted hazard ratio for the NCEP
definition was 4.62 (95% confidence interval [CI]: 3.90,
5.48) and that for the IDF definition was 4.59 (95% CI:
3.84, 5.50). When we limited the analyses to the subsam-
ple with fasting blood specimens (N = 788, 189 events),
the adjusted hazard ratios were 4.83 (95% CI: 3.46, 6.75)
for the NCEP definition and 5.62 (95% CI: 3.99, 7.92) for
the IDF definition. The hazard ratios for women were
larger than those for men only for the NCEP definition (p
interaction for sex and metabolic syndrome = 0.001 for
NCEP and 0.325 for IDF).
For the NCEP definition, we also investigated the effect of
using no cardiometabolic abnormalities as the reference
group on the hazard ratio. The adjusted hazard ratio for
Table 1: Selected characteristics for the subcohort, by incident diabetes status, European Prospective Investigation into Cancer and 
Nutrition-Potsdam 1994–1998 to 2005
Incident diabetes mellitus
No (N = 2099) Yes (N = 66)
Mean or % SD Mean or % SD p
Age (years) 49.5 8.8 55.9 7.0 <0.001
Waist circumference (cm) 85.0 12.4 98.6 11.2 <0.001
Total cholesterol (mg/dl) 173.3 37.4 183.3 36.3 0.028
Triglycerides (mg/dl) 110.5 74.9 179.8 154.4 <0.001
High-density lipoprotein cholesterol (mg/dl) 48.1 13.0 40.3 10.6 <0.001
Systolic blood pressure (mm Hg) 128.6 17.4 143.8 21.2 <0.001
Glucose (mg/dl) 86.9 15.0 103.4 21.5 <0.001
C-reactive protein (mg/l) 1.6 2.7 4.4 7.3 <0.001
Physical activity (h/w) 6.1 5.8 5.6 6.0 0.307
%, Female 62.4 -- 50.0 -- 0.053
%, Heavy occupational activity 6.1 -- 0.0 -- 0.031
%, Never smokers 47.7 -- 39.4 -- 0.211
%, Alcohol use >40 g/d 8.3 -- 10.6 -- 0.497
Number of NCEP components <0.001
01 9 . 6 - - 0 . 0 - -
1–2 59.6 -- 24.2 --
≥ 32 0 . 8 - - 7 5 . 8 - -
%, Metabolic syndrome (NCEP) 20.8 -- 75.8 -- <0.001
%, Metabolic syndrome (IDF) 26.8 -- 74.2 -- <0.001
IDF = International Diabetes Federation, NCEP = National Cholesterol Education Program, SD = standard deviation
Table 2: Adjusted hazard ratios (95% confidence interval) for incident diabetes by status of the metabolic syndrome among 
participants aged 35–65 years, European Prospective Investigation into Cancer and Nutrition-Potsdam Study 194–1998 to 2005
Definition of metabolic syndrome Hazard ratio (95% CI)
National Cholesterol Education Program
Total (697 events, 2796 participants) 4.622 (3.895, 5.484)
Men (397 events, 1186 participants) 3.687 (2.943, 4.619)
Women (300 events, 1610 participants) 6.075 (4.646, 7.944)
International Diabetes Federation
Total (697 events, 2796 participants) 4.593 (3.838, 5.498)
Men (397 events, 1186 participants) 4.279 (3.370, 5.434)
Women (300 events, 1610 participants) 4.785 (3.615, 6.333)
Adjusted for age, sex, educational status, smoking status, alcohol use, physical activity, and concentrations of total cholesterol and C-reactive 
protein.Cardiovascular Diabetology 2008, 7:35 http://www.cardiab.com/content/7/1/35
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having 3 or more abnormalities increased to 22.50 (95%
CI: 11.21, 45.19) (Figure 1).
Abdominal obesity (HR = 2.81; 95% CI: 2.36, 3.33) and
hyperglycemia (HR = 2.67; 95% CI: 2.26, 3.16) were the
two strongest predictors of incident diabetes and were of
approximately similar magnitude (Table 3). They were
followed in order of decreasing magnitude by low high-
density lipoprotein cholesterol, high blood pressure, and
hypertriglyceridemia. The magnitude of the hazard ratio
for the NCEP definition of abdominal obesity was larger
among women than men (p interaction for abdominal
obesity = 0.016), but the hazard ratio for the IDF defini-
tion of abdominal obesity was similar for men and
women (p interaction for abdominal obesity = 0.370).
Furthermore, the magnitude of the hazard ratio for hyper-
Hazard ratios and 95% confidence intervals for incident diabetes among 2796 participants aged 35–65 years, by number of car- diometabolic abnormalities, EPIC-Potsdam 1994–1998 to 2005 Figure 1
Hazard ratios and 95% confidence intervals for incident diabetes among 2796 participants aged 35–65 years, by 
number of cardiometabolic abnormalities, EPIC-Potsdam 1994–1998 to 2005. Hazard ratios are adjusted for age, 
sex, educational status, smoking status, alcohol use, occupational activity, physical activity, concentrations of total cholesterol 
and C-reactive protein, and other components of the metabolic syndrome.
Table 3: Adjusted hazard ratios (95% confidence interval) for incident diabetes by components of the metabolic syndrome among 
participants aged 35–65 years, European Prospective Investigation into Cancer and Nutrition-Potsdam Study 194–1998 to 2005
N NCEP 
abdominal 
obesity
IDF abdominal 
obesity
Hypertriglycerid
emia
Low high-density 
lipoprotein 
cholesterol
High blood 
pressure
Hyperglycemia
Total 2796 2.81 (2.36, 3.33) 2.90 (2.29, 3.67) 1.26 (1.06, 1.51) 1.97 (1.64, 2.37) 1.52 (1.22, 1.90) 2.67 (2.26, 3.16)
Men 1186 2.44 (1.97, 3.02) 2.73 (2.02, 3.69) 1.20 (0.94, 1.52) 2.02 (1.58, 2.59) 1.95 (1.40, 2.72) 2.45 (1.97, 3.05)
Women 1610 3.62 (2.67, 4.90) 3. 05 (2.05, 4.52) 1.36 (1.04, 1.78) 1.95 (1.46, 2.61) 1.20 (0.89, 1.63) 3.21 (2.45, 4.19)
IDF = International Diabetes Federation; NCEP = National Cholesterol Education Program.
Adjusted for age, sex, educational status, smoking status, alcohol use, occupational activity, physical activity, concentrations of total cholesterol and 
C-reactive protein, and other components of the metabolic syndrome.Cardiovascular Diabetology 2008, 7:35 http://www.cardiab.com/content/7/1/35
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glycemia was higher among women than men (p interac-
tion for hyperglycemia = 0.030). For the other three
components, there was no evidence for a gender effect (p
for all interactions terms >0.05).
We also examined whether the metabolic syndrome pro-
vided prediction beyond that of its components. In mod-
els that included the five components in dichotomized
form, as well as the covariates, the adjusted hazard ratio
for the NCEP definition was 1.13 (95% CI: 0.84, 1.52) (p
Wald chi-square = 0.418) and that for the IDF definition
was 1.28 (95% CI: 0.94, 1.76) (p Wald chi-square =
0.123).
Discussion
In this large prospective study, the metabolic syndrome
was a strong predictor of incident diabetes. The NCEP but
not the IDF definition of the metabolic syndrome proved
to be a stronger predictor among women than men. Par-
ticularly, noteworthy was the high risk of developing dia-
betes when participants with the metabolic syndrome
were compared with those who had no cardiometabolic
abnormalities.
Our estimates of relative risk for the IDF definition were
in line with those from other prospective studies that have
examined the associations between the metabolic syn-
drome and incident diabetes. Most previous studies
reported measures of relative risk ranging from 2.05 to
10.5 [5-13]. In comparison, the hazard ratio for all partic-
ipants included in the analyses in the EPIC-Potsdam study
was 4.59.
Few studies have examined the gender-specific risks for
incident diabetes associated with the metabolic syndrome
[22,23]. In the Beijing Project, the magnitude of the rela-
tive risks was higher among men than women for all four
definitions used in that study [22]. However, it was not
clear whether the gender differences were statistically sig-
nificant. In the Framingham Offspring Study, the relative
risk among men was 6.92 (95% CI: 4.47–10.81) and that
among women was 6.90 (95% CI: 4.35–10.94) [23]. In
contrast, we found that women had a significantly higher
hazard ratio when we used the NCEP definition but had a
similar hazard ratio when we used the IDF definition. This
difference likely emanates from one or both of the two key
differences between the definitions. The first major differ-
ence is that, of the five components that are included in
the two definitions, abdominal obesity is the only one
that is defined differently. We did find a significant gender
interaction with abdominal obesity for the NCEP defini-
tion but not the IDF definition. The second important dif-
ference is that the IDF definition requires the presence of
abdominal obesity in contrast to the NCEP definition,
which weights all components equally. Additional studies
are needed to get a clearer picture of potential gender dif-
ferences in the risk for incident diabetes associated with
the metabolic syndrome.
The high hazard ratio for diabetes when we contrasted
participants with 3 or more cardiometabolic abnormali-
ties with those who had no abnormalities is consistent
with results from previous studies. In the West of Scotland
Coronary Prevention Study, men with 4 or more abnor-
malities had a hazard ration of 24.4 (95% CI: 7.53–79.6)
[24]. In the Framingham Offspring Study, odds ratios for
those with 3 or more cardiometabolic abnormalities were
23.83 (95% CI: 5.80–98.01) among men and 29.69 (95%
CI: 9.10–96.85) among women [23]. However, in an
analysis of data from the British Regional Heart Study,
participants with 3 abnormalities had a hazard ratio of
4.56 (95% CI: 2.48, 8.78) and participants with 4 or 5
abnormalities had a hazard ratio of 10.88 (95% CI: 5.77,
20.50) compared with participants who had no abnor-
malities [25]. In the Caerphilly Cohort Study, the relative
risks associated were 7.05 for 3 abnormalities and 13.39
for 4 abnormalities [26].
In other studies, impaired fasting glucose was the abnor-
mality most strongly associated with incident diabetes [8-
11,22,23,27]. In the EPIC-Potsdam study, however, the
hazard ratio for abdominal obesity was slightly higher
than that for impaired fasting glucose.
In general, the few studies that have investigated the issue
of whether the metabolic syndrome adds additional pre-
diction for incident diabetes once its components are
accounted for have concluded that this is not the case.
However, only the WHO definition in men added addi-
tional prediction in a study conducted in Mauritius, and
only the EGIR definition in men added additional predic-
tion in the AusDiab [10,11]. In the EPIC-Potsdam study,
the metabolic syndrome was also not a significant predic-
tor of incident diabetes once its components were taken
into account.
The hazard ratios for the two definitions were similar in
our study. Given the high concordance in classifying par-
ticipants as having or not having the syndrome in our
study population, this is perhaps not too surprising. Most
of the previous studies have found slightly higher esti-
mates of relative risk for the NCEP definition than the IDF
definition [5-13]. However, our calculations of the sum-
mary relative risks yielded estimates of a similar magni-
tude. Thus, the two definitions performed approximately
similarly in predicting risk of new-onset diabetes.
Our study is subject to several limitations. First, incident
diabetes was defined on the basis of self-reported data that
were confirmed by physicians. Thus, we failed to detectCardiovascular Diabetology 2008, 7:35 http://www.cardiab.com/content/7/1/35
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undiagnosed cases of diabetes. However, if the association
between the metabolic syndrome and undiagnosed diabe-
tes was similar to that of diagnosed diabetes than our haz-
ard ratios should be accurate [28]. Second, measurements
of concentrations of glucose and triglycerides were meas-
ured on both fasting and nonfasting participants. We
adjusted the threshold for defining diabetes to reflect non-
fasting status. However, the percentage of participants
with hypertriglyceridemia was likely overestimated. How-
ever, the subanalysis conducted on fasting participants
who had fasted yielded similar hazard ratios to those of
the full sample. Third, we were unable to adjust for some
potential confounders such as family history of diabetes.
Considerable controversy surrounds the metabolic syn-
drome. Criticism has been leveled at the syndrome in part
because of the dichotomization of the variables that have
been included in the definitions. Undoubtedly the act of
dichotomization results in some loss of predictive infor-
mation and likely leads to a hereto undetermined under-
estimation of risk. Until the time comes when better risk
functions that incorporate the continuous nature of these
variables are developed and accepted by the medical com-
munity or when diabetes risk scores are conclusively
shown to outperform the metabolic syndrome in predict-
ing risk, a relatively simple tool like the metabolic syn-
drome can serve a useful function.
In conclusion, the metabolic syndrome was a strong pre-
dictor of incident diabetes in the EPIC-Potsdam study.
The expression of this risk was particularly pronounced
when participants with the metabolic syndrome were con-
trasted with those who had no cardiometabolic abnor-
malities. These findings reinforce the point that maximal
risk reduction for contracting diabetes can be achieved by
maintaining all five components that are included in the
NCEP and IDF definitions of the metabolic syndrome in
the normal range.
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